董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| William B. Horne | 男 | Chairman of the Board | 57 | 5.00万美元 | 未持股 | 2025-07-22 |
| Milton C. Ault, III | 男 | Vice Chairman of the Board | 54 | 2.50万美元 | 未持股 | 2025-07-22 |
| Stephan Jackman | 男 | Chief Executive Officer and Director | 49 | 46.83万美元 | 未持股 | 2025-07-22 |
| Henry C. W. Nisser | 男 | Executive Vice President, General Counsel and Director | 56 | 5.00万美元 | 未持股 | 2025-07-22 |
| Lynne Fahey McGrath | 女 | Director | 70 | 2.50万美元 | 未持股 | 2025-07-22 |
| Jeffrey Oram | 男 | Director | 57 | 2.50万美元 | 未持股 | 2025-07-22 |
| Andrew H. Woo | 男 | Director | 62 | 2.50万美元 | 未持股 | 2025-07-22 |
| Mark Gustafson | 男 | Director | 65 | 2.50万美元 | 未持股 | 2025-07-22 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Kenneth S. Cragun | 男 | Senior Vice President of Finance | 64 | 10.00万美元 | 未持股 | 2025-07-22 |
| Stephan Jackman | 男 | Chief Executive Officer and Director | 49 | 46.83万美元 | 未持股 | 2025-07-22 |
| Henry C. W. Nisser | 男 | Executive Vice President, General Counsel and Director | 56 | 5.00万美元 | 未持股 | 2025-07-22 |
| David Katzoff | 男 | Chief Financial Officer | 63 | 15.00万美元 | 未持股 | 2025-07-22 |
董事简历
中英对照 | 中文 | 英文- William B. Horne
-
William B. Horne自2016年6月起担任Alzamend Neuro, Inc.董事。霍恩先生自2016年6月至2018年12月担任首席财务官。霍恩先生自2016年10月起担任奥特环球董事会成员。2018年1月，霍恩先生被任命为奥特环球首席财务官，直至2020年8月，霍恩先生被任命为奥特环球首席财务官辞去首席财务官职务，并被任命为总裁。2021年1月12日，Horne先生辞去了Ault Global总裁的职务，并成为首席执行官。霍恩先生是雪崩公司的董事兼首席财务官。Horne先生曾于2008年1月至2013年5月在医疗保健和高科技领域的多家公司担任首席财务官一职，其中包括一家私营多元化医疗科技公司OptimisCorp.Horne先生于2005年6月至2008年10月担任医疗设备公司患者安全技术公司首席财务官，2007年1月至2008年4月担任临时首席执行官。他在患者安全技术方面发挥双重作用，霍恩先生直接负责非核心资产剥离、资本融资和债务重组。霍恩先生还曾在普华永道律师事务所担任监督职务。Horne先生持有西雅图大学会计学学士学位。
William B. Horne has served as a member of Board since October 2016. On January 19, 2021, Mr. Horne resigned as President and was appointed as the Chief Executive Officer. On Augt 19, 2020, Mr. Horne resigned as Chief Financial Officer and was appointed as President. He was appointed as Chief Financial Officer on January 25, 2018. Prior to his appointment as Chief Financial Officer, Mr. Horne served as one of independent directors. Mr. Horne has served as the Chief Executive Officer and on the board of directors of Ault Disruptive since its incorporation in February 2021. Mr. Horne has served on the board of directors of Gresham Worldwide, Inc. ("GWW") since September 2022. Mr. Horne has served on the board of directors of Alzamend since June 1, 2016 and became its Chairman of the board upon consummation of its IPO. Mr. Horne has served as a director and Chief Financial Officer of AVLP from June 2016 until its liquidation in March 2025. Mr. Horne has served as a director and Chief Financial Officer of A&C since October 2017. He served as the Chief Financial Officer of Targeted Medical Pharma, Inc. from Augt 2013 to May 2019.Mr. Horne has a Bachelor of Arts Magna Cum Laude in Accounting from Seattle University. - William B. Horne自2016年6月起担任Alzamend Neuro, Inc.董事。霍恩先生自2016年6月至2018年12月担任首席财务官。霍恩先生自2016年10月起担任奥特环球董事会成员。2018年1月，霍恩先生被任命为奥特环球首席财务官，直至2020年8月，霍恩先生被任命为奥特环球首席财务官辞去首席财务官职务，并被任命为总裁。2021年1月12日，Horne先生辞去了Ault Global总裁的职务，并成为首席执行官。霍恩先生是雪崩公司的董事兼首席财务官。Horne先生曾于2008年1月至2013年5月在医疗保健和高科技领域的多家公司担任首席财务官一职，其中包括一家私营多元化医疗科技公司OptimisCorp.Horne先生于2005年6月至2008年10月担任医疗设备公司患者安全技术公司首席财务官，2007年1月至2008年4月担任临时首席执行官。他在患者安全技术方面发挥双重作用，霍恩先生直接负责非核心资产剥离、资本融资和债务重组。霍恩先生还曾在普华永道律师事务所担任监督职务。Horne先生持有西雅图大学会计学学士学位。
- William B. Horne has served as a member of Board since October 2016. On January 19, 2021, Mr. Horne resigned as President and was appointed as the Chief Executive Officer. On Augt 19, 2020, Mr. Horne resigned as Chief Financial Officer and was appointed as President. He was appointed as Chief Financial Officer on January 25, 2018. Prior to his appointment as Chief Financial Officer, Mr. Horne served as one of independent directors. Mr. Horne has served as the Chief Executive Officer and on the board of directors of Ault Disruptive since its incorporation in February 2021. Mr. Horne has served on the board of directors of Gresham Worldwide, Inc. ("GWW") since September 2022. Mr. Horne has served on the board of directors of Alzamend since June 1, 2016 and became its Chairman of the board upon consummation of its IPO. Mr. Horne has served as a director and Chief Financial Officer of AVLP from June 2016 until its liquidation in March 2025. Mr. Horne has served as a director and Chief Financial Officer of A&C since October 2017. He served as the Chief Financial Officer of Targeted Medical Pharma, Inc. from Augt 2013 to May 2019.Mr. Horne has a Bachelor of Arts Magna Cum Laude in Accounting from Seattle University.
- Milton C. Ault, III
-
Milton C. Ault, III创立了Alzamend Neuro, Inc，自成立之日起担任Alzamend Neuro, Inc.的董事会主席，自2018年11月起担任Alzamend Neuro, Inc.的执行主席。Ault先生是一位经验丰富的商业专业人士和企业家，他花了超过27年的时间在各种金融市场（包括股票、固定收益、大宗商品和房地产）中确定价值。2017年3月，Ault先生被任命为Ault Global董事会执行主席，2017年12月，Ault先生被任命为Ault Global首席执行官，2021年1月12日，Ault先生恢复了执行主席的职务。Ault先生自2015年12月起担任控股公司Ault&Company的董事长，自2014年9月起担任上市公司“Avalanche”Avalanche International Corp.的董事长。自2011年1月起，Ault先生一直担任家族理财办公室MCKEA Holdings，LLC的业务发展副总裁。奥尔特曾与许多上市公司和私营公司进行过咨询，这些公司从发展阶段到成熟的业务都有，他为每一家公司提供了丰富的经验。
Milton C. Ault, III has served as Executive Chairman since January 2021. Beten December 2017 and January 2021, Mr. Ault was Chief Executive Officer and beten March 2017 and December 2017, Mr. Ault served as Executive Chairman. Mr. Ault has served as a director of Alzamend Neuro, Inc., an issuer listed on Nasdaq ("Alzamend") since January 2024. Mr. Ault is Alzamend's founder and served as Chairman of the Board and a director from inception in 2016 until its initial public offering in June 2021. Since May 2025, Mr. Ault has served as a director of Universal Safety Products, Inc., an issuer listed on the NYSE American ("Universal Safety"). Mr. Ault has served as Chairman and Chief Executive Officer of A&C since December 2015, and as Chairman of Avalanche International Corp. ("AVLP") from September 2014 until its liquidation in March 2025. Since January 2011, Mr. Ault has been the Vice President of Biness Development for MCKEA Holdings, LLC, a family office. Since January 2024, Mr. Ault has served as the Chairman and Chief Executive Officer of RiskOn International, Inc., an issuer quoted on the OTCPK ("ROI"). Mr. Ault served as the Chairman of the Board of Ault Disruptive Technologies Corporation, an issuer previoly listed on the NYSE American ("Ault Disruptive") since its incorporation in February 2021 until October 2024. Beten April 2023 and September 2024, Mr. Ault served as the Executive Chairman of the board of directors of Algorhythm Holdings, Inc., an issuer listed on Nasdaq ("RIME"). - Milton C. Ault, III创立了Alzamend Neuro, Inc，自成立之日起担任Alzamend Neuro, Inc.的董事会主席，自2018年11月起担任Alzamend Neuro, Inc.的执行主席。Ault先生是一位经验丰富的商业专业人士和企业家，他花了超过27年的时间在各种金融市场（包括股票、固定收益、大宗商品和房地产）中确定价值。2017年3月，Ault先生被任命为Ault Global董事会执行主席，2017年12月，Ault先生被任命为Ault Global首席执行官，2021年1月12日，Ault先生恢复了执行主席的职务。Ault先生自2015年12月起担任控股公司Ault&Company的董事长，自2014年9月起担任上市公司“Avalanche”Avalanche International Corp.的董事长。自2011年1月起，Ault先生一直担任家族理财办公室MCKEA Holdings，LLC的业务发展副总裁。奥尔特曾与许多上市公司和私营公司进行过咨询，这些公司从发展阶段到成熟的业务都有，他为每一家公司提供了丰富的经验。
- Milton C. Ault, III has served as Executive Chairman since January 2021. Beten December 2017 and January 2021, Mr. Ault was Chief Executive Officer and beten March 2017 and December 2017, Mr. Ault served as Executive Chairman. Mr. Ault has served as a director of Alzamend Neuro, Inc., an issuer listed on Nasdaq ("Alzamend") since January 2024. Mr. Ault is Alzamend's founder and served as Chairman of the Board and a director from inception in 2016 until its initial public offering in June 2021. Since May 2025, Mr. Ault has served as a director of Universal Safety Products, Inc., an issuer listed on the NYSE American ("Universal Safety"). Mr. Ault has served as Chairman and Chief Executive Officer of A&C since December 2015, and as Chairman of Avalanche International Corp. ("AVLP") from September 2014 until its liquidation in March 2025. Since January 2011, Mr. Ault has been the Vice President of Biness Development for MCKEA Holdings, LLC, a family office. Since January 2024, Mr. Ault has served as the Chairman and Chief Executive Officer of RiskOn International, Inc., an issuer quoted on the OTCPK ("ROI"). Mr. Ault served as the Chairman of the Board of Ault Disruptive Technologies Corporation, an issuer previoly listed on the NYSE American ("Ault Disruptive") since its incorporation in February 2021 until October 2024. Beten April 2023 and September 2024, Mr. Ault served as the Executive Chairman of the board of directors of Algorhythm Holdings, Inc., an issuer listed on Nasdaq ("RIME").
- Stephan Jackman
-
Stephan Jackman于2018年11月加入Alzamend Neuro, Inc，担任首席执行官。Jackman先生于2020年9月当选为董事。他在从研究阶段到市场和商业化的治疗方法、产品和项目的开发过程中发挥了复杂的作用。杰克曼先生表现出专注于为内部和外部利益相关者创造价值的双重关注，同时发展战略联盟和跨职能团队，以实现和超越目标。在加入Alzamend Neuro, Inc.公司之前，从2017年10月到2018年11月，Jackman先生是Ennaid Therapeutics的首席运营官，Ennaid Therapeutics是一家新兴的生物制药公司，专注于治疗寨卡病毒和登革热病毒等蚊媒传染病。2015年10月至2017年10月，Jackman先生担任Exit 9 Technologies的首席运营官，Exit 9 Technologies是一家科技初创公司，拥有一个连接零售商、出版商和客户的数字平台。此外，2014年8月至2015年10月，他还是一名独立项目和管理顾问，协助初创企业、财富500强企业和非营利组织实施重大战略计划。他还在诺华制药公司担任越来越重要的职务USA，SBM管理服务和家庭干预服务。杰克曼先生拥有史蒂文斯理工学院管理学硕士和机械工程学士学位。
Stephan Jackman,joined company as Chief Executive Officer in November 2018. Mr. Jackman was elected as a director in September 2020. He has played an intricate role in the development of therapeutic treatments, products and programs from the research stage to market and commercialization. Mr. Jackman has demonstrated a dedicated dual focus of creating value for internal and external stakeholders while developing strategic alliances and cross-function teams to meet and exceed goals. Prior to joining Alzamend Neuro, Inc. company, from October 2017 to November 2018, Mr. Jackman was the Chief Operating Officer of Ennaid Therapeutics, an emerging biopharmaceutical company focusing on cures for mosquito borne infectious diseases such as Zika and Dengue viruses. From October 2015 to October 2017, Mr. Jackman was Chief Operating Officer of Exit 9 Technologies, a technology startup with a digital platform that connects retailers, publishers and customers. Additionally, from August 2014 to October 2015, he was an independent project and management consultant assisting startups, Fortune 500 companies and non-profits with major strategic initiatives. He has also held positions of increasing responsibility at Novartis Pharmaceuticals Corporation, L'Oréal USA, SBM Management Services and Family Intervention Services. Mr. Jackman holds a Master of Science in Management and a Bachelor of Engineering in Mechanical Engineering from Stevens Institute of Technology. - Stephan Jackman于2018年11月加入Alzamend Neuro, Inc，担任首席执行官。Jackman先生于2020年9月当选为董事。他在从研究阶段到市场和商业化的治疗方法、产品和项目的开发过程中发挥了复杂的作用。杰克曼先生表现出专注于为内部和外部利益相关者创造价值的双重关注，同时发展战略联盟和跨职能团队，以实现和超越目标。在加入Alzamend Neuro, Inc.公司之前，从2017年10月到2018年11月，Jackman先生是Ennaid Therapeutics的首席运营官，Ennaid Therapeutics是一家新兴的生物制药公司，专注于治疗寨卡病毒和登革热病毒等蚊媒传染病。2015年10月至2017年10月，Jackman先生担任Exit 9 Technologies的首席运营官，Exit 9 Technologies是一家科技初创公司，拥有一个连接零售商、出版商和客户的数字平台。此外，2014年8月至2015年10月，他还是一名独立项目和管理顾问，协助初创企业、财富500强企业和非营利组织实施重大战略计划。他还在诺华制药公司担任越来越重要的职务USA，SBM管理服务和家庭干预服务。杰克曼先生拥有史蒂文斯理工学院管理学硕士和机械工程学士学位。
- Stephan Jackman,joined company as Chief Executive Officer in November 2018. Mr. Jackman was elected as a director in September 2020. He has played an intricate role in the development of therapeutic treatments, products and programs from the research stage to market and commercialization. Mr. Jackman has demonstrated a dedicated dual focus of creating value for internal and external stakeholders while developing strategic alliances and cross-function teams to meet and exceed goals. Prior to joining Alzamend Neuro, Inc. company, from October 2017 to November 2018, Mr. Jackman was the Chief Operating Officer of Ennaid Therapeutics, an emerging biopharmaceutical company focusing on cures for mosquito borne infectious diseases such as Zika and Dengue viruses. From October 2015 to October 2017, Mr. Jackman was Chief Operating Officer of Exit 9 Technologies, a technology startup with a digital platform that connects retailers, publishers and customers. Additionally, from August 2014 to October 2015, he was an independent project and management consultant assisting startups, Fortune 500 companies and non-profits with major strategic initiatives. He has also held positions of increasing responsibility at Novartis Pharmaceuticals Corporation, L'Oréal USA, SBM Management Services and Family Intervention Services. Mr. Jackman holds a Master of Science in Management and a Bachelor of Engineering in Mechanical Engineering from Stevens Institute of Technology.
- Henry C. W. Nisser
-
Henry C. W. Nisser，他于2023年4月5日被任命为The Singing Machine Company, Inc.董事。Nisser先生自2021年1月起担任AAI总裁，自2020年9月起担任AAI董事会成员，自2019年5月起担任AAI总法律顾问。Nisser先生此前于2019年5月至2021年1月担任AAI的执行副总裁。Nisser先生自2023年3月起担任BitNile Metaverse, Inc.（纳斯达克上市公司，运营BitNile.com Metaverse平台）的总裁、总法律顾问和董事会成员。Nisser先生是Avalanche的执行副总裁兼总法律顾问。自ADTC于2021年2月成立以来，Nisser先生一直担任总裁、总法律顾问和董事会成员。Nisser先生自2020年9月1日起担任Alzamend董事会成员，并自2019年5月1日起担任其执行副总裁兼总法律顾问。从2011年10月到2019年4月，Nisser先生是Sichenzia Ross Ference LLP（“SRF”）的合伙人，这是一家位于纽约市的律师事务所。在SRF任职期间，他的业务重点是国内和国际公司法，尤其关注美国证券合规、公共和私人并购、股权和债务融资以及公司治理。Nisser先生起草和谈判了与重组、股票和资产购买、契约、公开和私人发行、要约收购和私人交易相关的各种协议。Nisser先生还代表客户为评估并购交易而设立的特别委员会，并就其信托责任向这些委员会成员提供建议。Nisser先生精通法语和瑞典语，同时精通意大利语。Nisser先生于1992年获得Connecticut College的学士学位，主修国际关系和经济学。他于1999年获得白金汉大学法学院的法学学士学位。
Henry C. W. Nisser,has served as Executive Vice President and General Counsel on a part-time basis since May 2019. Mr. Nisser was appointed as a director in September 2020. Since May 2019, Mr. Nisser has served as the Executive Vice President and General Counsel of HDI and as one of its directors since September 2020; he became HDI's President on January 12, 2021. Since March 2023, Mr. Nisser has served as the President, General Counsel and director of RiskOn International, Inc., an OTCPK quoted company ("ROI"), a social gaming platform. Between February 2021 and October 2024, Mr. Nisser served as the President, General Counsel and a director of Ault Disruptive. Between April 2023 and August 2024, Mr. Nisser served as a director of Algorhythm Holdings, Inc., ("RIME"), a Nasdaq listed company. Between May 2019 and March 2025, Mr. Nisser served as the Executive Vice President and General Counsel of Avalanche International Corp., a publicly traded Nevada company categorized as a "voluntary filer" (not required to file periodic reports) ("Avalanche"). Between December 15, 2021 and March 16, 2022, Mr. Nisser served as Chief Executive Officer and on the board of directors of TurnOnGreen, Inc. Mr. Nisser has served as a President, General Counsel and a director of Ault & Co. since May 2019. From October 2011 through April 2019, Mr. Nisser was an associate and subsequently a partner with Sichenzia Ross Ference LLP, a law firm in New York. While with this law firm, his practice was concentrated on national and international corporate law, with a particular focus on U.S. securities compliance, public as well as private M&A, equity and debt financings and corporate governance. Mr. Nisser received his B.A. degree from Connecticut College, where he majored in International Relations and Economics. He received his LL.B. from University of Buckingham School of Law in the United Kingdom. - Henry C. W. Nisser，他于2023年4月5日被任命为The Singing Machine Company, Inc.董事。Nisser先生自2021年1月起担任AAI总裁，自2020年9月起担任AAI董事会成员，自2019年5月起担任AAI总法律顾问。Nisser先生此前于2019年5月至2021年1月担任AAI的执行副总裁。Nisser先生自2023年3月起担任BitNile Metaverse, Inc.（纳斯达克上市公司，运营BitNile.com Metaverse平台）的总裁、总法律顾问和董事会成员。Nisser先生是Avalanche的执行副总裁兼总法律顾问。自ADTC于2021年2月成立以来，Nisser先生一直担任总裁、总法律顾问和董事会成员。Nisser先生自2020年9月1日起担任Alzamend董事会成员，并自2019年5月1日起担任其执行副总裁兼总法律顾问。从2011年10月到2019年4月，Nisser先生是Sichenzia Ross Ference LLP（“SRF”）的合伙人，这是一家位于纽约市的律师事务所。在SRF任职期间，他的业务重点是国内和国际公司法，尤其关注美国证券合规、公共和私人并购、股权和债务融资以及公司治理。Nisser先生起草和谈判了与重组、股票和资产购买、契约、公开和私人发行、要约收购和私人交易相关的各种协议。Nisser先生还代表客户为评估并购交易而设立的特别委员会，并就其信托责任向这些委员会成员提供建议。Nisser先生精通法语和瑞典语，同时精通意大利语。Nisser先生于1992年获得Connecticut College的学士学位，主修国际关系和经济学。他于1999年获得白金汉大学法学院的法学学士学位。
- Henry C. W. Nisser,has served as Executive Vice President and General Counsel on a part-time basis since May 2019. Mr. Nisser was appointed as a director in September 2020. Since May 2019, Mr. Nisser has served as the Executive Vice President and General Counsel of HDI and as one of its directors since September 2020; he became HDI's President on January 12, 2021. Since March 2023, Mr. Nisser has served as the President, General Counsel and director of RiskOn International, Inc., an OTCPK quoted company ("ROI"), a social gaming platform. Between February 2021 and October 2024, Mr. Nisser served as the President, General Counsel and a director of Ault Disruptive. Between April 2023 and August 2024, Mr. Nisser served as a director of Algorhythm Holdings, Inc., ("RIME"), a Nasdaq listed company. Between May 2019 and March 2025, Mr. Nisser served as the Executive Vice President and General Counsel of Avalanche International Corp., a publicly traded Nevada company categorized as a "voluntary filer" (not required to file periodic reports) ("Avalanche"). Between December 15, 2021 and March 16, 2022, Mr. Nisser served as Chief Executive Officer and on the board of directors of TurnOnGreen, Inc. Mr. Nisser has served as a President, General Counsel and a director of Ault & Co. since May 2019. From October 2011 through April 2019, Mr. Nisser was an associate and subsequently a partner with Sichenzia Ross Ference LLP, a law firm in New York. While with this law firm, his practice was concentrated on national and international corporate law, with a particular focus on U.S. securities compliance, public as well as private M&A, equity and debt financings and corporate governance. Mr. Nisser received his B.A. degree from Connecticut College, where he majored in International Relations and Economics. He received his LL.B. from University of Buckingham School of Law in the United Kingdom.
- Lynne Fahey McGrath
-
Lynne Fahey McGrath已同意加入Alzamend Neuro, Inc.的董事会。McGrath博士自2020年5月起担任生物技术产品开发公司Nobias Therapeutics，Inc.执行团队的顾问，并于2018年8月至2020年3月担任生物技术咨询公司FoxKiser，LLC的监管顾问。McGrath博士曾任Regenxbio，Inc.监管事务副总裁。在2015年4月至2019年期间，她负责其基因治疗产品组合的全球战略。此前，她在诺华公司担任高级职位，包括副总裁，2003至2015年4月，诺华消费者健康管理机构的全球负责人和美国诺瓦蒂斯肿瘤学监管部门负责人麦克格拉斯博士获得了康涅狄格大学的学士学位，来自罗格斯大学环境科学系的M.S.和M.P.H.和博士。来自新泽西医学和牙科大学罗伯特伍德约翰逊医学院的公共卫生。
Lynne Fahey McGrath,joined Board in June 2021. Dr. McGrath is currently on the Strategic Advisory to Bryleos, Inc. (June 2022-present), a private corporation developing drugs for diseases of aging. Dr. McGrath has served as a consultant to various companies in the biopharmaceutical industry, including: to the executive team of Nobias Therapeutics, Inc., a biotechnology product development company, between May 2020 and December 2021; a regulatory consultant with FoxKiser, LLC, a biotechnology consulting firm, from August 2018 to March 2020; and a regulatory consultant with Catalyst Healthcare Consulting, a biotechnology consulting firm, from 2020 to 2021. Dr. McGrath was a senior executive and Vice President of Regulatory Affairs at Regenxbio, Inc., where she headed global strategy for its portfolio of gene therapy products, from April 2015 to July 2018. Previously, she held senior positions at Novartis Corporation including Vice President, Global Head of Regulatory and Medical Affairs at Novartis Consumer Health and Vice President and U.S. Head of Regulatory Affairs at Novartis Oncology from 2003 to April 2015. Dr. McGrath received a B.S. degree from the University of Connecticut, M.S. in Environmental Science from Rutgers University and M.P.H. and Ph.D. in Public Health from the University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School. - Lynne Fahey McGrath已同意加入Alzamend Neuro, Inc.的董事会。McGrath博士自2020年5月起担任生物技术产品开发公司Nobias Therapeutics，Inc.执行团队的顾问，并于2018年8月至2020年3月担任生物技术咨询公司FoxKiser，LLC的监管顾问。McGrath博士曾任Regenxbio，Inc.监管事务副总裁。在2015年4月至2019年期间，她负责其基因治疗产品组合的全球战略。此前，她在诺华公司担任高级职位，包括副总裁，2003至2015年4月，诺华消费者健康管理机构的全球负责人和美国诺瓦蒂斯肿瘤学监管部门负责人麦克格拉斯博士获得了康涅狄格大学的学士学位，来自罗格斯大学环境科学系的M.S.和M.P.H.和博士。来自新泽西医学和牙科大学罗伯特伍德约翰逊医学院的公共卫生。
- Lynne Fahey McGrath,joined Board in June 2021. Dr. McGrath is currently on the Strategic Advisory to Bryleos, Inc. (June 2022-present), a private corporation developing drugs for diseases of aging. Dr. McGrath has served as a consultant to various companies in the biopharmaceutical industry, including: to the executive team of Nobias Therapeutics, Inc., a biotechnology product development company, between May 2020 and December 2021; a regulatory consultant with FoxKiser, LLC, a biotechnology consulting firm, from August 2018 to March 2020; and a regulatory consultant with Catalyst Healthcare Consulting, a biotechnology consulting firm, from 2020 to 2021. Dr. McGrath was a senior executive and Vice President of Regulatory Affairs at Regenxbio, Inc., where she headed global strategy for its portfolio of gene therapy products, from April 2015 to July 2018. Previously, she held senior positions at Novartis Corporation including Vice President, Global Head of Regulatory and Medical Affairs at Novartis Consumer Health and Vice President and U.S. Head of Regulatory Affairs at Novartis Oncology from 2003 to April 2015. Dr. McGrath received a B.S. degree from the University of Connecticut, M.S. in Environmental Science from Rutgers University and M.P.H. and Ph.D. in Public Health from the University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School.
- Jeffrey Oram
-
Jeffrey Oram已同意加入Alzamend Neuro, Inc.的董事会。奥拉姆先生是一名商业专业人士，拥有超过25年的企业、私人和机构投资经验。奥拉姆过去13年一直在机构房地产资本市场工作。自2016年以来，他一直担任私人房地产投资和经纪公司Godby Realtors的负责人。2010年至2018年，奥拉姆担任新泽西州投资委员会（newjersey State Investment Council）执行委员，负责监管新泽西州800亿美元养老基金的投资。2011年至2016年，他在高力国际担任执行董事总经理，2009年至2011年，他在Marcus和Millichap担任董事，2003年至2009年，他在CB Richard Ellis担任第一副总裁。Oram先生获得了普林斯顿大学生物科学学士学位。
Jeffrey Oram,joined Board in June 2021. Mr. Oram is a business professional with more than 25 years of corporate, private and institutional investment experience. Mr. Oram has spent the last 13 years in the institutional real estate capital markets. Since 2016, he has been a Principal at Godby Realtors, a private real estate investment and brokerage firm. From 2010 to 2018, Mr. Oram served as an Executive Member of the New Jersey State Investment Council, which oversees the investment of the State of New Jersey's pension fund. From 2011 to 2016, he served as Executive Managing Director at Colliers International, from 2009 to 2011 he served as Director at Marcus and Millichap, and from 2003 to 2009, served as First Vice President at CB Richard Ellis. Mr. Oram received a Bachelor of Science degree in Biology from Princeton University. - Jeffrey Oram已同意加入Alzamend Neuro, Inc.的董事会。奥拉姆先生是一名商业专业人士，拥有超过25年的企业、私人和机构投资经验。奥拉姆过去13年一直在机构房地产资本市场工作。自2016年以来，他一直担任私人房地产投资和经纪公司Godby Realtors的负责人。2010年至2018年，奥拉姆担任新泽西州投资委员会（newjersey State Investment Council）执行委员，负责监管新泽西州800亿美元养老基金的投资。2011年至2016年，他在高力国际担任执行董事总经理，2009年至2011年，他在Marcus和Millichap担任董事，2003年至2009年，他在CB Richard Ellis担任第一副总裁。Oram先生获得了普林斯顿大学生物科学学士学位。
- Jeffrey Oram,joined Board in June 2021. Mr. Oram is a business professional with more than 25 years of corporate, private and institutional investment experience. Mr. Oram has spent the last 13 years in the institutional real estate capital markets. Since 2016, he has been a Principal at Godby Realtors, a private real estate investment and brokerage firm. From 2010 to 2018, Mr. Oram served as an Executive Member of the New Jersey State Investment Council, which oversees the investment of the State of New Jersey's pension fund. From 2011 to 2016, he served as Executive Managing Director at Colliers International, from 2009 to 2011 he served as Director at Marcus and Millichap, and from 2003 to 2009, served as First Vice President at CB Richard Ellis. Mr. Oram received a Bachelor of Science degree in Biology from Princeton University.
- Andrew H. Woo
-
Andrew H. Woo已同意加入Andrew H. Woo的董事会。吴博士在圣莫尼卡神经咨询公司从事私人执业，并在加州大学洛杉矶分校大卫格芬医学院和西达斯西奈医学中心担任神经病学临床助理教授。他还担任美国多发性硬化症协会及其国际指导委员会的董事会成员。他曾在2006年、2012年和2019年获得加州大学洛杉矶分校临床教师教学奖，并被美国消费者研究委员会（Consumer Research Council of America）和Castle Connolly America's Top Doctors 2006 2007 2010-2021 Southern California Super Doctors since 2008和洛杉矶杂志Top Doctors列入美国顶级医生名单。他是阿布扎比Muntada国际研讨会的特邀发言人。Woo博士从康奈尔大学获得学士学位，完成医学博士和博士学位。在Neuroimmunology布朗大学分子与细胞生物学系。他完成了在纽约威尔康奈尔长老会医院/康奈尔医学中心的医学实习，在加州大学洛杉矶分校的神经病学住院医师，以及在加州大学洛杉矶港分校的神经生理学奖学金。
Andrew H. Woo,joined Board in June 2021. Dr. Woo is in private practice at Santa Monica Neurological Consultants and serves as an Assistant Clinical Professor of Neurology at the David Geffen School of Medicine at UCLA and Cedars-Sinai Medical Center. He also serves on the board for the Multiple Sclerosis Association of America and its Navigating MS International Steering Committee. He has been presented with UCLA clinical faculty teaching awards in 2006, 2012 and 2019 and is listed in America's Top Physicians by the Consumer Research Council of America and Castle Connolly America's Top Doctors 2006, 2007, 2010-2021, Southern California Super Doctors since 2008, and Los Angeles Magazine Top Doctors. He is an invited speaker at the Muntada International Symposium in Abu Dhabi. Dr. Woo received his B.A. from Cornell University and completed his M.D. and Ph.D. in Neuroimmunology in the Department of Molecular and Cell Biology at Brown University. He completed his medicine internship at Weil-Cornell Presbyterian Hospital/Cornell Medical Center in New York, his neurology residency at UCLA, and his fellowship in neurophysiology at Harbor-UCLA. - Andrew H. Woo已同意加入Andrew H. Woo的董事会。吴博士在圣莫尼卡神经咨询公司从事私人执业，并在加州大学洛杉矶分校大卫格芬医学院和西达斯西奈医学中心担任神经病学临床助理教授。他还担任美国多发性硬化症协会及其国际指导委员会的董事会成员。他曾在2006年、2012年和2019年获得加州大学洛杉矶分校临床教师教学奖，并被美国消费者研究委员会（Consumer Research Council of America）和Castle Connolly America's Top Doctors 2006 2007 2010-2021 Southern California Super Doctors since 2008和洛杉矶杂志Top Doctors列入美国顶级医生名单。他是阿布扎比Muntada国际研讨会的特邀发言人。Woo博士从康奈尔大学获得学士学位，完成医学博士和博士学位。在Neuroimmunology布朗大学分子与细胞生物学系。他完成了在纽约威尔康奈尔长老会医院/康奈尔医学中心的医学实习，在加州大学洛杉矶分校的神经病学住院医师，以及在加州大学洛杉矶港分校的神经生理学奖学金。
- Andrew H. Woo,joined Board in June 2021. Dr. Woo is in private practice at Santa Monica Neurological Consultants and serves as an Assistant Clinical Professor of Neurology at the David Geffen School of Medicine at UCLA and Cedars-Sinai Medical Center. He also serves on the board for the Multiple Sclerosis Association of America and its Navigating MS International Steering Committee. He has been presented with UCLA clinical faculty teaching awards in 2006, 2012 and 2019 and is listed in America's Top Physicians by the Consumer Research Council of America and Castle Connolly America's Top Doctors 2006, 2007, 2010-2021, Southern California Super Doctors since 2008, and Los Angeles Magazine Top Doctors. He is an invited speaker at the Muntada International Symposium in Abu Dhabi. Dr. Woo received his B.A. from Cornell University and completed his M.D. and Ph.D. in Neuroimmunology in the Department of Molecular and Cell Biology at Brown University. He completed his medicine internship at Weil-Cornell Presbyterian Hospital/Cornell Medical Center in New York, his neurology residency at UCLA, and his fellowship in neurophysiology at Harbor-UCLA.
- Mark Gustafson
-
Mark Gustafson加入Alzamend Neuro, Inc.董事会，并于2021年6月成为审计委员会主席。Gustafson先生是一名特许专业会计师，拥有超过35年的公司、私营和上市公司经验。自2023年1月以来，Gustafson先生一直担任BrainLuxury，Inc.的董事和非执行董事长，该公司是一家开发和销售大脑营养素的美国私营公司。自2021年4月以来，Gustafson先生一直担任PharmaKure Limited的首席财务官，自2022年1月起担任董事，该公司是一家总部位于伦敦的私营生物制药公司，致力于治疗神经退行性疾病。2021年12月至今，Gustafson先生担任Ault Disruptive独立董事、审计委员会主席。自2020年6月以来，Gustafson先生担任Alpha Helium Inc.的创始人和董事，该公司是一家总部位于加拿大的私营公司氦气勘探公司。2014年至2020年，他担任伦敦证券交易所上市娱乐公司Challenger Acquisitions Limited的首席执行官。2010年至2012年，Gustafson先生担任多伦多证券交易所上市矿产勘探公司Euromax Resources Limited的总裁兼首席执行官。2005年至2009年担任纽约证券交易所上市油气勘探公司三角能源公司董事长兼首席执行官；2004年至2006年担任民营油气公司Torrent Energy Corporation总裁兼首席执行官；2001年至2002年担任两家民营油气公司Samson Oil & Gas和Peavine Resources财务顾问。1997年至1999年，Gustafson先生担任多伦多证券交易所上市油田服务公司Total 美国能源服务有限公司的总裁兼首席执行官。1993年至1995年，他担任多伦多证券交易所上市软件公司Q/media Software Corporation的首席财务官。1987年至1993年，他最初担任首席财务官，随后在多伦多证券交易所上市油田服务公司EnServ Corporation担任负责两个运营部门的副总裁。从1981年到1987年，他在阿尔伯塔省卡尔加里的普华永道担任审计经理。Gustafson先生在Wilfrid Laurier大学获得工商管理学士学位。Gustafson先生自1983年以来一直担任特许会计师。
Mark Gustafson,joined Board and became the Chairman of the Audit Committee in June 2021. Mr. Gustafson is a Chartered Professional Accountant with over 40 years of corporate, private and public company experience. Since July 2024, Mr. Gustafson has been a director of Altimist Capital Ltd., a private London (UK) based company focused on developing a proprietary trading platform under FCA authorization. Since June 2024, Mr. Gustafson has been the Chief Financial Officer of Orga Energy Ltd., a private oil and gas production company based in Calgary, Alberta. From January 2023 to June 2024, Mr. Gustafson was a director and non-executive Chairman of BrainLuxury, Inc., a private U.S. company. From April 2021 to October 2024, Mr. Gustafson was the Chief Financial Officer, and between January 2022 and July 2024, was a director, for PharmaKure Limited, a private London-based biopharmaceutical company. Between December 2021 and December 2023, Mr. Gustafson served as an independent director and Chairman of the Audit Committee of Ault Disruptive. From June 2020 to April 2024, Mr. Gustafson was a director of Alpha Helium Inc., a private Canadian-based company helium exploration company. From 2014 to 2020, he was the Chief Executive Officer of Challenger Acquisitions Limited, a London Stock Exchange listed entertainment company. From 2010 to 2012, Mr. Gustafson was the President and Chief Executive Officer of Euromax Resources Limited, a Toronto Stock Exchange listed mineral exploration company. From 2005 to 2009, he served as Chairman and Chief Executive Officer of Triangle Energy Corporation, a New York Stock Exchange listed oil and gas exploration company, from 2004 to 2006, he served as President and Chief Executive Officer of Torrent Energy Corporation, a private oil and gas company, and from 2001 to 2002, he served as a financial consultant for Samson Oil & Gas and Peavine Resources, two private oil and gas companies. From 1997 to 1999, Mr. Gustafson served as President and Chief Executive Officer of Total Energy Services Ltd., a Toronto Stock Exchange listed oilfield services company, from 1993 to 1995, he served as the Chief Financial Officer of Q/media Software Corporation, a Toronto Stock Exchange listed software company, and from 1987 to 1993, he served initially as the Chief Financial Officer and then as a Vice President in charge of two operating divisions at EnServ Corporation, a Toronto Stock Exchange listed oilfield services company. From 1981 to 1987, he served as an audit manager at Price Waterhouse in Calgary Alberta. Mr. Gustafson received his Bachelor of Business Administration from Wilfrid Laurier University. Mr. Gustafson has been a Chartered Accountant since 1983. - Mark Gustafson加入Alzamend Neuro, Inc.董事会，并于2021年6月成为审计委员会主席。Gustafson先生是一名特许专业会计师，拥有超过35年的公司、私营和上市公司经验。自2023年1月以来，Gustafson先生一直担任BrainLuxury，Inc.的董事和非执行董事长，该公司是一家开发和销售大脑营养素的美国私营公司。自2021年4月以来，Gustafson先生一直担任PharmaKure Limited的首席财务官，自2022年1月起担任董事，该公司是一家总部位于伦敦的私营生物制药公司，致力于治疗神经退行性疾病。2021年12月至今，Gustafson先生担任Ault Disruptive独立董事、审计委员会主席。自2020年6月以来，Gustafson先生担任Alpha Helium Inc.的创始人和董事，该公司是一家总部位于加拿大的私营公司氦气勘探公司。2014年至2020年，他担任伦敦证券交易所上市娱乐公司Challenger Acquisitions Limited的首席执行官。2010年至2012年，Gustafson先生担任多伦多证券交易所上市矿产勘探公司Euromax Resources Limited的总裁兼首席执行官。2005年至2009年担任纽约证券交易所上市油气勘探公司三角能源公司董事长兼首席执行官；2004年至2006年担任民营油气公司Torrent Energy Corporation总裁兼首席执行官；2001年至2002年担任两家民营油气公司Samson Oil & Gas和Peavine Resources财务顾问。1997年至1999年，Gustafson先生担任多伦多证券交易所上市油田服务公司Total 美国能源服务有限公司的总裁兼首席执行官。1993年至1995年，他担任多伦多证券交易所上市软件公司Q/media Software Corporation的首席财务官。1987年至1993年，他最初担任首席财务官，随后在多伦多证券交易所上市油田服务公司EnServ Corporation担任负责两个运营部门的副总裁。从1981年到1987年，他在阿尔伯塔省卡尔加里的普华永道担任审计经理。Gustafson先生在Wilfrid Laurier大学获得工商管理学士学位。Gustafson先生自1983年以来一直担任特许会计师。
- Mark Gustafson,joined Board and became the Chairman of the Audit Committee in June 2021. Mr. Gustafson is a Chartered Professional Accountant with over 40 years of corporate, private and public company experience. Since July 2024, Mr. Gustafson has been a director of Altimist Capital Ltd., a private London (UK) based company focused on developing a proprietary trading platform under FCA authorization. Since June 2024, Mr. Gustafson has been the Chief Financial Officer of Orga Energy Ltd., a private oil and gas production company based in Calgary, Alberta. From January 2023 to June 2024, Mr. Gustafson was a director and non-executive Chairman of BrainLuxury, Inc., a private U.S. company. From April 2021 to October 2024, Mr. Gustafson was the Chief Financial Officer, and between January 2022 and July 2024, was a director, for PharmaKure Limited, a private London-based biopharmaceutical company. Between December 2021 and December 2023, Mr. Gustafson served as an independent director and Chairman of the Audit Committee of Ault Disruptive. From June 2020 to April 2024, Mr. Gustafson was a director of Alpha Helium Inc., a private Canadian-based company helium exploration company. From 2014 to 2020, he was the Chief Executive Officer of Challenger Acquisitions Limited, a London Stock Exchange listed entertainment company. From 2010 to 2012, Mr. Gustafson was the President and Chief Executive Officer of Euromax Resources Limited, a Toronto Stock Exchange listed mineral exploration company. From 2005 to 2009, he served as Chairman and Chief Executive Officer of Triangle Energy Corporation, a New York Stock Exchange listed oil and gas exploration company, from 2004 to 2006, he served as President and Chief Executive Officer of Torrent Energy Corporation, a private oil and gas company, and from 2001 to 2002, he served as a financial consultant for Samson Oil & Gas and Peavine Resources, two private oil and gas companies. From 1997 to 1999, Mr. Gustafson served as President and Chief Executive Officer of Total Energy Services Ltd., a Toronto Stock Exchange listed oilfield services company, from 1993 to 1995, he served as the Chief Financial Officer of Q/media Software Corporation, a Toronto Stock Exchange listed software company, and from 1987 to 1993, he served initially as the Chief Financial Officer and then as a Vice President in charge of two operating divisions at EnServ Corporation, a Toronto Stock Exchange listed oilfield services company. From 1981 to 1987, he served as an audit manager at Price Waterhouse in Calgary Alberta. Mr. Gustafson received his Bachelor of Business Administration from Wilfrid Laurier University. Mr. Gustafson has been a Chartered Accountant since 1983.
高管简历
中英对照 | 中文 | 英文- Kenneth S. Cragun
Kenneth S. Cragun于2018年12月兼职加入Alzamend Neuro, Inc.自2016年10月起，他担任Hardesty，LLC的首席财务官合伙人，Hardesty是一家全国性的高管服务公司。他在Hardesty的工作包括担任CorVel Corporation的首席财务官，CorVel Corporation是一家上市公司，也是技术驱动领域的全国领先者，与医疗保健相关的风险管理项目，以及私人结构设计和优化软件公司RISA Tech，Inc.的项目。2009年4月至2016年9月，Cragun先生还担任两家纳斯达克上市公司Local Corporation的首席财务官。Local Corporation运营着美国100强网站Local.com，2006年6月至2009年3月，Modtech Holdings，Inc.运营着模块化建筑供应商。在此之前，他在MIVA，Inc.、ImproveNet，Inc.、NetCharge Inc.、C-Cube Microsystems，Inc.和3-Com Corporation担任财务领导职务，并承担越来越多的责任。克拉贡先生目前是奥尔特环球的首席财务官，任职于Verb Technology Company，Inc.的董事会和审计委员会主席。克拉贡先生在德勤开始了他的职业生涯。Cragun先生持有科罗拉多州立大学Pueblo理学学士学位。
Kenneth S. Cragun,joined company on a part-time basis in December 2018. Between February 2021 and October 2024, Mr. Cragun served as the Chief Financial Officer of Ault Disruptive. Since August 2020, Mr. Cragun has served as the Chief Financial Officer of HDI and between October 2018 and August 2020, served as its Chief Accounting Officer. Since September 2018, Mr. Cragun has served on the board of directors and Chairman of the Audit Committee of Verb Technology Company, Inc. Between July 2022 and September 2024, Mr. Cragun served on the board of directors of RIME. He served as a CFO Partner at Hardesty, LLC, a national executive services firm between October 2016 and October 2018. His assignments at Hardesty included serving as Chief Financial Officer of CorVel Corporation, a publicly traded company and a nationwide leader in technology driven, healthcare-related, risk management programs, and of RISA Tech, Inc., a private structural design and optimization software company. Mr. Cragun was also Chief Financial Officer of two Nasdaq-traded companies, Local Corporation, from April 2009 to September 2016, which operated Local.com, a U.S. top 100 website, and Modtech Holdings, Inc., from June 2006 to March 2009, a supplier of modular buildings. Prior thereto, he had financial leadership roles with increasing responsibilities at MIVA, Inc., ImproveNet, Inc., NetCharge Inc., C-Cube Microsystems, Inc, and 3-Com Corporation. Mr. Cragun began his professional career at Deloitte. Mr. Cragun holds a Bachelor of Science degree in accounting from Colorado State University-Pueblo.- Kenneth S. Cragun于2018年12月兼职加入Alzamend Neuro, Inc.自2016年10月起，他担任Hardesty，LLC的首席财务官合伙人，Hardesty是一家全国性的高管服务公司。他在Hardesty的工作包括担任CorVel Corporation的首席财务官，CorVel Corporation是一家上市公司，也是技术驱动领域的全国领先者，与医疗保健相关的风险管理项目，以及私人结构设计和优化软件公司RISA Tech，Inc.的项目。2009年4月至2016年9月，Cragun先生还担任两家纳斯达克上市公司Local Corporation的首席财务官。Local Corporation运营着美国100强网站Local.com，2006年6月至2009年3月，Modtech Holdings，Inc.运营着模块化建筑供应商。在此之前，他在MIVA，Inc.、ImproveNet，Inc.、NetCharge Inc.、C-Cube Microsystems，Inc.和3-Com Corporation担任财务领导职务，并承担越来越多的责任。克拉贡先生目前是奥尔特环球的首席财务官，任职于Verb Technology Company，Inc.的董事会和审计委员会主席。克拉贡先生在德勤开始了他的职业生涯。Cragun先生持有科罗拉多州立大学Pueblo理学学士学位。
- Kenneth S. Cragun,joined company on a part-time basis in December 2018. Between February 2021 and October 2024, Mr. Cragun served as the Chief Financial Officer of Ault Disruptive. Since August 2020, Mr. Cragun has served as the Chief Financial Officer of HDI and between October 2018 and August 2020, served as its Chief Accounting Officer. Since September 2018, Mr. Cragun has served on the board of directors and Chairman of the Audit Committee of Verb Technology Company, Inc. Between July 2022 and September 2024, Mr. Cragun served on the board of directors of RIME. He served as a CFO Partner at Hardesty, LLC, a national executive services firm between October 2016 and October 2018. His assignments at Hardesty included serving as Chief Financial Officer of CorVel Corporation, a publicly traded company and a nationwide leader in technology driven, healthcare-related, risk management programs, and of RISA Tech, Inc., a private structural design and optimization software company. Mr. Cragun was also Chief Financial Officer of two Nasdaq-traded companies, Local Corporation, from April 2009 to September 2016, which operated Local.com, a U.S. top 100 website, and Modtech Holdings, Inc., from June 2006 to March 2009, a supplier of modular buildings. Prior thereto, he had financial leadership roles with increasing responsibilities at MIVA, Inc., ImproveNet, Inc., NetCharge Inc., C-Cube Microsystems, Inc, and 3-Com Corporation. Mr. Cragun began his professional career at Deloitte. Mr. Cragun holds a Bachelor of Science degree in accounting from Colorado State University-Pueblo.
- Stephan Jackman
Stephan Jackman于2018年11月加入Alzamend Neuro, Inc，担任首席执行官。Jackman先生于2020年9月当选为董事。他在从研究阶段到市场和商业化的治疗方法、产品和项目的开发过程中发挥了复杂的作用。杰克曼先生表现出专注于为内部和外部利益相关者创造价值的双重关注，同时发展战略联盟和跨职能团队，以实现和超越目标。在加入Alzamend Neuro, Inc.公司之前，从2017年10月到2018年11月，Jackman先生是Ennaid Therapeutics的首席运营官，Ennaid Therapeutics是一家新兴的生物制药公司，专注于治疗寨卡病毒和登革热病毒等蚊媒传染病。2015年10月至2017年10月，Jackman先生担任Exit 9 Technologies的首席运营官，Exit 9 Technologies是一家科技初创公司，拥有一个连接零售商、出版商和客户的数字平台。此外，2014年8月至2015年10月，他还是一名独立项目和管理顾问，协助初创企业、财富500强企业和非营利组织实施重大战略计划。他还在诺华制药公司担任越来越重要的职务USA，SBM管理服务和家庭干预服务。杰克曼先生拥有史蒂文斯理工学院管理学硕士和机械工程学士学位。
Stephan Jackman,joined company as Chief Executive Officer in November 2018. Mr. Jackman was elected as a director in September 2020. He has played an intricate role in the development of therapeutic treatments, products and programs from the research stage to market and commercialization. Mr. Jackman has demonstrated a dedicated dual focus of creating value for internal and external stakeholders while developing strategic alliances and cross-function teams to meet and exceed goals. Prior to joining Alzamend Neuro, Inc. company, from October 2017 to November 2018, Mr. Jackman was the Chief Operating Officer of Ennaid Therapeutics, an emerging biopharmaceutical company focusing on cures for mosquito borne infectious diseases such as Zika and Dengue viruses. From October 2015 to October 2017, Mr. Jackman was Chief Operating Officer of Exit 9 Technologies, a technology startup with a digital platform that connects retailers, publishers and customers. Additionally, from August 2014 to October 2015, he was an independent project and management consultant assisting startups, Fortune 500 companies and non-profits with major strategic initiatives. He has also held positions of increasing responsibility at Novartis Pharmaceuticals Corporation, L'Oréal USA, SBM Management Services and Family Intervention Services. Mr. Jackman holds a Master of Science in Management and a Bachelor of Engineering in Mechanical Engineering from Stevens Institute of Technology.- Stephan Jackman于2018年11月加入Alzamend Neuro, Inc，担任首席执行官。Jackman先生于2020年9月当选为董事。他在从研究阶段到市场和商业化的治疗方法、产品和项目的开发过程中发挥了复杂的作用。杰克曼先生表现出专注于为内部和外部利益相关者创造价值的双重关注，同时发展战略联盟和跨职能团队，以实现和超越目标。在加入Alzamend Neuro, Inc.公司之前，从2017年10月到2018年11月，Jackman先生是Ennaid Therapeutics的首席运营官，Ennaid Therapeutics是一家新兴的生物制药公司，专注于治疗寨卡病毒和登革热病毒等蚊媒传染病。2015年10月至2017年10月，Jackman先生担任Exit 9 Technologies的首席运营官，Exit 9 Technologies是一家科技初创公司，拥有一个连接零售商、出版商和客户的数字平台。此外，2014年8月至2015年10月，他还是一名独立项目和管理顾问，协助初创企业、财富500强企业和非营利组织实施重大战略计划。他还在诺华制药公司担任越来越重要的职务USA，SBM管理服务和家庭干预服务。杰克曼先生拥有史蒂文斯理工学院管理学硕士和机械工程学士学位。
- Stephan Jackman,joined company as Chief Executive Officer in November 2018. Mr. Jackman was elected as a director in September 2020. He has played an intricate role in the development of therapeutic treatments, products and programs from the research stage to market and commercialization. Mr. Jackman has demonstrated a dedicated dual focus of creating value for internal and external stakeholders while developing strategic alliances and cross-function teams to meet and exceed goals. Prior to joining Alzamend Neuro, Inc. company, from October 2017 to November 2018, Mr. Jackman was the Chief Operating Officer of Ennaid Therapeutics, an emerging biopharmaceutical company focusing on cures for mosquito borne infectious diseases such as Zika and Dengue viruses. From October 2015 to October 2017, Mr. Jackman was Chief Operating Officer of Exit 9 Technologies, a technology startup with a digital platform that connects retailers, publishers and customers. Additionally, from August 2014 to October 2015, he was an independent project and management consultant assisting startups, Fortune 500 companies and non-profits with major strategic initiatives. He has also held positions of increasing responsibility at Novartis Pharmaceuticals Corporation, L'Oréal USA, SBM Management Services and Family Intervention Services. Mr. Jackman holds a Master of Science in Management and a Bachelor of Engineering in Mechanical Engineering from Stevens Institute of Technology.
- Henry C. W. Nisser
Henry C. W. Nisser，他于2023年4月5日被任命为The Singing Machine Company, Inc.董事。Nisser先生自2021年1月起担任AAI总裁，自2020年9月起担任AAI董事会成员，自2019年5月起担任AAI总法律顾问。Nisser先生此前于2019年5月至2021年1月担任AAI的执行副总裁。Nisser先生自2023年3月起担任BitNile Metaverse, Inc.（纳斯达克上市公司，运营BitNile.com Metaverse平台）的总裁、总法律顾问和董事会成员。Nisser先生是Avalanche的执行副总裁兼总法律顾问。自ADTC于2021年2月成立以来，Nisser先生一直担任总裁、总法律顾问和董事会成员。Nisser先生自2020年9月1日起担任Alzamend董事会成员，并自2019年5月1日起担任其执行副总裁兼总法律顾问。从2011年10月到2019年4月，Nisser先生是Sichenzia Ross Ference LLP（“SRF”）的合伙人，这是一家位于纽约市的律师事务所。在SRF任职期间，他的业务重点是国内和国际公司法，尤其关注美国证券合规、公共和私人并购、股权和债务融资以及公司治理。Nisser先生起草和谈判了与重组、股票和资产购买、契约、公开和私人发行、要约收购和私人交易相关的各种协议。Nisser先生还代表客户为评估并购交易而设立的特别委员会，并就其信托责任向这些委员会成员提供建议。Nisser先生精通法语和瑞典语，同时精通意大利语。Nisser先生于1992年获得Connecticut College的学士学位，主修国际关系和经济学。他于1999年获得白金汉大学法学院的法学学士学位。
Henry C. W. Nisser,has served as Executive Vice President and General Counsel on a part-time basis since May 2019. Mr. Nisser was appointed as a director in September 2020. Since May 2019, Mr. Nisser has served as the Executive Vice President and General Counsel of HDI and as one of its directors since September 2020; he became HDI's President on January 12, 2021. Since March 2023, Mr. Nisser has served as the President, General Counsel and director of RiskOn International, Inc., an OTCPK quoted company ("ROI"), a social gaming platform. Between February 2021 and October 2024, Mr. Nisser served as the President, General Counsel and a director of Ault Disruptive. Between April 2023 and August 2024, Mr. Nisser served as a director of Algorhythm Holdings, Inc., ("RIME"), a Nasdaq listed company. Between May 2019 and March 2025, Mr. Nisser served as the Executive Vice President and General Counsel of Avalanche International Corp., a publicly traded Nevada company categorized as a "voluntary filer" (not required to file periodic reports) ("Avalanche"). Between December 15, 2021 and March 16, 2022, Mr. Nisser served as Chief Executive Officer and on the board of directors of TurnOnGreen, Inc. Mr. Nisser has served as a President, General Counsel and a director of Ault & Co. since May 2019. From October 2011 through April 2019, Mr. Nisser was an associate and subsequently a partner with Sichenzia Ross Ference LLP, a law firm in New York. While with this law firm, his practice was concentrated on national and international corporate law, with a particular focus on U.S. securities compliance, public as well as private M&A, equity and debt financings and corporate governance. Mr. Nisser received his B.A. degree from Connecticut College, where he majored in International Relations and Economics. He received his LL.B. from University of Buckingham School of Law in the United Kingdom.- Henry C. W. Nisser，他于2023年4月5日被任命为The Singing Machine Company, Inc.董事。Nisser先生自2021年1月起担任AAI总裁，自2020年9月起担任AAI董事会成员，自2019年5月起担任AAI总法律顾问。Nisser先生此前于2019年5月至2021年1月担任AAI的执行副总裁。Nisser先生自2023年3月起担任BitNile Metaverse, Inc.（纳斯达克上市公司，运营BitNile.com Metaverse平台）的总裁、总法律顾问和董事会成员。Nisser先生是Avalanche的执行副总裁兼总法律顾问。自ADTC于2021年2月成立以来，Nisser先生一直担任总裁、总法律顾问和董事会成员。Nisser先生自2020年9月1日起担任Alzamend董事会成员，并自2019年5月1日起担任其执行副总裁兼总法律顾问。从2011年10月到2019年4月，Nisser先生是Sichenzia Ross Ference LLP（“SRF”）的合伙人，这是一家位于纽约市的律师事务所。在SRF任职期间，他的业务重点是国内和国际公司法，尤其关注美国证券合规、公共和私人并购、股权和债务融资以及公司治理。Nisser先生起草和谈判了与重组、股票和资产购买、契约、公开和私人发行、要约收购和私人交易相关的各种协议。Nisser先生还代表客户为评估并购交易而设立的特别委员会，并就其信托责任向这些委员会成员提供建议。Nisser先生精通法语和瑞典语，同时精通意大利语。Nisser先生于1992年获得Connecticut College的学士学位，主修国际关系和经济学。他于1999年获得白金汉大学法学院的法学学士学位。
- Henry C. W. Nisser,has served as Executive Vice President and General Counsel on a part-time basis since May 2019. Mr. Nisser was appointed as a director in September 2020. Since May 2019, Mr. Nisser has served as the Executive Vice President and General Counsel of HDI and as one of its directors since September 2020; he became HDI's President on January 12, 2021. Since March 2023, Mr. Nisser has served as the President, General Counsel and director of RiskOn International, Inc., an OTCPK quoted company ("ROI"), a social gaming platform. Between February 2021 and October 2024, Mr. Nisser served as the President, General Counsel and a director of Ault Disruptive. Between April 2023 and August 2024, Mr. Nisser served as a director of Algorhythm Holdings, Inc., ("RIME"), a Nasdaq listed company. Between May 2019 and March 2025, Mr. Nisser served as the Executive Vice President and General Counsel of Avalanche International Corp., a publicly traded Nevada company categorized as a "voluntary filer" (not required to file periodic reports) ("Avalanche"). Between December 15, 2021 and March 16, 2022, Mr. Nisser served as Chief Executive Officer and on the board of directors of TurnOnGreen, Inc. Mr. Nisser has served as a President, General Counsel and a director of Ault & Co. since May 2019. From October 2011 through April 2019, Mr. Nisser was an associate and subsequently a partner with Sichenzia Ross Ference LLP, a law firm in New York. While with this law firm, his practice was concentrated on national and international corporate law, with a particular focus on U.S. securities compliance, public as well as private M&A, equity and debt financings and corporate governance. Mr. Nisser received his B.A. degree from Connecticut College, where he majored in International Relations and Economics. He received his LL.B. from University of Buckingham School of Law in the United Kingdom.
- David Katzoff
David Katzoff自成立以来一直担任Ault Disruptive Technologies Corporation的财务副总裁，自2019年1月起担任BitNile的财务高级副总裁。自2020年12月起，他还是Alzamend Neuro的首席运营官，曾于2019年11月至2020年12月担任运营高级副总裁。Katzoff先生于2015年至2018年12月担任Lumina Media，LLC的首席财务官，Lumina Media，LLC是一家私营媒体公司，也是生活方式出版物的出版商，并于2003年至2017年担任当地公司的财务副总裁。Katzoff先生在加州大学戴维斯分校获得工商管理学士学位。
David Katzoff,joined company on a part-time basis in November 2019, serving as Senior Vice President of Operations from November 2019 to December 2020, as Chief Operating Officer from December 2020 until August 2022 and currently serves as Alzamend Neuro, Inc. Chief Financial Officer since August 2022. Mr. Katzoff has served as Senior Vice President of Finance of HDI since January 2019. From February 2021 to October 2024, Mr. Katzoff served as the Vice President of Finance of Ault Disruptive Technologies Corporation, a publicly traded special purpose acquisition company ("Ault Disruptive"). From December 2021 to September 2023, Mr. Katzoff served as the Chief Financial Officer of TurnOnGreen, Inc. (formerly, Imperalis Holding Corp.) ("TurnOnGreen"), an OTCPK quoted company. From 2015 to 2018, Mr. Katzoff served as Chief Financial Officer of Lumina Media, LLC, a privately-held media company and publisher of life-style publications. From 2003 to 2017, Mr. Katzoff served a Vice President of Finance of Local Corporation, a publicly-held local search company. Mr. Katzoff received a B.S. degree in Business Management from the University of California at Davis.- David Katzoff自成立以来一直担任Ault Disruptive Technologies Corporation的财务副总裁，自2019年1月起担任BitNile的财务高级副总裁。自2020年12月起，他还是Alzamend Neuro的首席运营官，曾于2019年11月至2020年12月担任运营高级副总裁。Katzoff先生于2015年至2018年12月担任Lumina Media，LLC的首席财务官，Lumina Media，LLC是一家私营媒体公司，也是生活方式出版物的出版商，并于2003年至2017年担任当地公司的财务副总裁。Katzoff先生在加州大学戴维斯分校获得工商管理学士学位。
- David Katzoff,joined company on a part-time basis in November 2019, serving as Senior Vice President of Operations from November 2019 to December 2020, as Chief Operating Officer from December 2020 until August 2022 and currently serves as Alzamend Neuro, Inc. Chief Financial Officer since August 2022. Mr. Katzoff has served as Senior Vice President of Finance of HDI since January 2019. From February 2021 to October 2024, Mr. Katzoff served as the Vice President of Finance of Ault Disruptive Technologies Corporation, a publicly traded special purpose acquisition company ("Ault Disruptive"). From December 2021 to September 2023, Mr. Katzoff served as the Chief Financial Officer of TurnOnGreen, Inc. (formerly, Imperalis Holding Corp.) ("TurnOnGreen"), an OTCPK quoted company. From 2015 to 2018, Mr. Katzoff served as Chief Financial Officer of Lumina Media, LLC, a privately-held media company and publisher of life-style publications. From 2003 to 2017, Mr. Katzoff served a Vice President of Finance of Local Corporation, a publicly-held local search company. Mr. Katzoff received a B.S. degree in Business Management from the University of California at Davis.